Educational guide
5-Amino-1MQ Peptide: NNMT Inhibition, NAD+ Preservation, and Metabolic Research Applications
A single enzyme quietly redirects the flow of cellular energy — and blocking it may reshape how researchers think about fat metabolism, muscle aging, and NAD+ biology. That enzyme is nicotinamide N-methyltransferase (NNMT), and the compound drawing the most at
This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.
A single enzyme quietly redirects the flow of cellular energy — and blocking it may reshape how researchers think about fat metabolism, muscle aging, and NAD+ biology. That enzyme is nicotinamide N-methyltransferase (NNMT), and the compound drawing the most attention in this space is 5-Amino-1MQ.
As of 2026, the 5-Amino-1MQ peptide — spanning NNMT inhibition, NAD+ preservation, and metabolic research applications — has generated a focused body of preclinical evidence that positions it as one of the more mechanistically interesting small molecules in metabolic science.
Key Takeaways
5-Amino-1MQ selectively inhibits NNMT, an enzyme that consumes methyl groups and depletes NAD+ precursors in metabolically active tissues.
Preclinical studies show dose-dependent fat loss, improved insulin sensitivity, and reduced liver fat without changes in food intake.
Muscle regeneration data from aged mouse models is compelling, with peak torque improvements near 70% and grip strength gains up to 60% when combined with exercise.
No human clinical trials have been published or registered as of 2026; all data remain preclinical.
5-Amino-1MQ is classified as a research compound and is not FDA-approved for any therapeutic use.
How NNMT Inhibition Drives NAD+ Preservation
NNMT catalyzes the methylation of nicotinamide, converting it to 1-methylnicotinamide (1-MNA) and effectively removing it from the NAD+ biosynthesis pathway. When NNMT is overactive — as it tends to be in obese and aged tissues — this process accelerates NAD+ precursor depletion, impairing mitochondrial function and energy output.
5-Amino-1MQ works by selectively binding to NNMT's active site, slowing this drain. The result is a measurable increase in intracellular NAD+ levels, which supports mitochondrial respiration, activates sirtuins, and improves overall metabolic efficiency.
"Blocking NNMT is not simply about preserving a molecule — it is about restoring the signaling environment that governs how cells burn fuel and repair themselves."
This mechanism distinguishes 5-Amino-1MQ from direct NAD+ precursor supplementation. Rather than flooding cells with nicotinamide riboside or NMN, it reduces the rate at which NAD+ precursors are diverted away from synthesis. For researchers exploring NAD+ biology and metabolic signaling, this upstream approach offers a distinct angle worth examining.
Key pharmacokinetic data from rat studies:
Oral bioavailability
38.4%
Half-life
4-7 hours (route-dependent)
Tissue distribution
Adipose, muscle, liver confirmed
Preclinical Evidence: Fat Loss, Muscle, and Metabolic Health
The preclinical record for 5-Amino-1MQ across NNMT inhibition, NAD+ preservation, and metabolic research applications spans several well-designed animal studies.
Obesity and fat metabolism:
A 2018 study found that 20 mg/kg/day of 5-Amino-1MQ reversed diet-induced obesity in mice without reducing food intake. This is significant because it suggests a thermogenic or metabolic shift rather than appetite suppression. A 2024 dose-finding study extended this work, demonstrating 28-day treatment produced dose-dependent weight loss, improved glucose tolerance, better insulin sensitivity, and measurable reductions in hepatic steatosis.
When combined with caloric restriction, NNMT inhibition normalized adiposity faster than either intervention alone and produced a distinct gut microbiome shift enriched in Lactobacillus species.
Muscle regeneration and aging:
A 2019 study in aged mice showed NNMT inhibition doubled myofiber cross-sectional area and improved peak muscle torque by approximately 70%.
A 2024 follow-up reported a 40% improvement in grip strength in sedentary aged mice, rising to 60% when paired with exercise.
These findings make 5-Amino-1MQ relevant to researchers studying sarcopenia and age-related muscle decline. This complements work being done with compounds like MOTS-c, a mitochondrial peptide that also targets energy metabolism in aging tissue.
Researchers building metabolic stacks may also find value in reviewing the scientific evidence around NAD+ supplementation and how upstream inhibition strategies compare to direct precursor loading.
Research Limitations and Where 5-Amino-1MQ Fits in 2026
The most important limitation of 5-Amino-1MQ research is straightforward: as of 2026, no human clinical trials have been published or registered. Every data point discussed above comes from rodent models. Translating these findings to human physiology requires controlled trials that do not yet exist.
5-Amino-1MQ is not FDA-approved and is classified strictly as a research compound. Its safety profile in humans is unknown.
That said, its mechanism fits logically into current metabolic research frameworks. Researchers interested in longevity peptide research will recognize NNMT inhibition as a credible target given the enzyme's known upregulation in obesity, aging, and metabolic disease states.
For those sourcing research compounds, peptide purity testing remains a non-negotiable step before any preclinical work begins. Researchers can also explore the full catalog of available research peptides to review current compound specifications.
5-Amino-1MQ may also pair meaningfully with compounds targeting adjacent pathways. Research on SS-31, a mitochondrial-targeted peptide, addresses oxidative stress at the inner mitochondrial membrane — a complementary mechanism to the NAD+ preservation strategy of NNMT inhibition.
Conclusion
5-Amino-1MQ occupies a genuinely interesting position in metabolic research. Its mechanism — reducing NNMT activity to preserve NAD+ precursors and improve mitochondrial function — is well-supported at the molecular level, and preclinical data across obesity, insulin resistance, liver health, and muscle aging are consistent and encouraging.
Actionable next steps for researchers:
Review the 2024 dose-finding data carefully before designing rodent study protocols.
Pair NNMT inhibition research with gut microbiome analysis, given the Lactobacillus enrichment findings.
Prioritize third-party purity verification for all research-grade compounds.
Monitor clinical trial registries for the first human studies, which remain the critical missing piece.
Consider how 5-Amino-1MQ fits within broader metabolic stacks targeting NAD+ biology, mitochondrial function, and adipose tissue regulation.
The compound is not a clinical solution yet. It is a research priority — and in 2026, that distinction matters.